Agreement Creates New Bridge Between North Carolina And China
RESEARCH TRIANGLE PARK, N.C., May 20 /PRNewswire/ -- The Hamner Institutes for Health Sciences has signed an agreement with China Medical City to create the Hamner-China Medical City Institute for International Drug Development. Building on strengths of the two organizations in translational research, business development, and education, the Institute will help to produce new biomedical technologies that benefit the United States and People's Republic of China as well as the rest of the world.
During the first phase of this agreement, the Institute for International Drug Development will be established at The Hamner's campus in Research Triangle Park (RTP), North Carolina, and will focus on preclinical drug development and compliance with FDA regulatory standards. After the partners validate research capabilities and new technologies at The Hamner campus, they will transfer them to China Medical City, a new life science park located in the Yangtze River Delta north of Shanghai.
In 2008, The Hamner launched a Bioscience Accelerator on its 56-acre campus in the heart of RTP. There are two initial start-ups: BioMedomics, a diagnostics company started by Chinese-American scientists, and b3bio, a spinout from
Newsummit Biopharma, one of China Medical City's premier partners, is establishing its North American business center in The Hamner's Bioscience Accelerator. Newsummit Biopharma is a contract research and technology development company whose service platform includes support for commercialization, intellectual property, funding, and staffing in science and technology parks throughout China.
The partnership with China Medical City and Newsummit Biopharma creates a vital bridge of opportunity between North Carolina and China. Acknowledged worldwide as a major hub of biotechnolog
|SOURCE Hamner Institutes for Health Sciences|
Copyright©2009 PR Newswire.
All rights reserved